Wnt and the Wnt signaling pathway in bone development and disease

被引:185
|
作者
Wang, Yiping [1 ,2 ]
Li, Yi-Ping [1 ]
Paulson, Christie [1 ]
Shao, Jian-Zhong [2 ]
Zhang, Xiaoling [3 ,4 ]
Wu, Mengrui [1 ,2 ]
Chen, Wei [1 ]
机构
[1] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA
[2] Zhejiang Univ, Life Sci Coll, Inst Genet, Hangzhou 310058, Zhejiang, Peoples R China
[3] Chinese Acad Sci, SIBS, Key Lab Stem Cell Biol, Inst Hlth Sci, Shanghai 200025, Peoples R China
[4] SJTUSM, Shanghai 200025, Peoples R China
来源
基金
美国国家卫生研究院;
关键词
OSTEOPOROSIS-PSEUDOGLIOMA SYNDROME; FRIZZLED-RELATED PROTEIN-1; SPLIT-HAND/FOOT MALFORMATION; RECEPTOR-RELATED PROTEIN-5; FOCAL DERMAL HYPOPLASIA; REGULATES CHONDROCYTE MATURATION; HOMOZYGOUS MISSENSE MUTATION; EMBRYONIC AXIS FORMATION; APICAL ECTODERMAL RIDGE; BETA-CATENIN STABILITY;
D O I
10.2741/4214
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Wnt signaling affects both bone modeling, which occurs during development, and bone remodeling, which is a lifelong process involving tissue renewal. Wnt signals are especially known to affect the differentiation of osteoblasts. In this review, we summarize recent advances in understanding the mechanisms of Wnt signaling, which is divided into two major branches: the canonical pathway and the noncanonical pathway. The canonical pathway is also called the Wnt/beta-catenin pathway. There are two major noncanonical pathways: the Wnt-planar cell polarity pathway (Wnt-PCP pathway) and the Wnt-calcium pathway (Wnt-Ca2+ pathway). This review also discusses how Wnt ligands, receptors, intracellular effectors, transcription factors, and antagonists affect both the bone modeling and bone remodeling processes. We also review the role of Wnt ligands, receptors, intracellular effectors, transcription factors, and antagonists in bone as demonstrated in mouse models. Disrupted Wnt signaling is linked to several bone diseases, including osteoporosis, van Buchem disease, and sclerosteosis. Studying the mechanism of Wnt signaling and its interactions with other signaling pathways in bone will provide potential therapeutic targets to treat these bone diseases.
引用
收藏
页码:379 / 407
页数:29
相关论文
共 50 条
  • [21] Wnt Signaling in Kidney Development and Disease
    Wang, Yongping
    Zhou, Chengji J.
    Liu, Youhua
    WNT SIGNALING IN HEALTH AND DISEASE, 2018, 153 : 181 - 207
  • [22] Wnt/β-catenin signaling in development and disease
    Clevers, Hans
    CELL, 2006, 127 (03) : 469 - 480
  • [23] Hyperthyroidism and Wnt Signaling Pathway: Influence on Bone Remodeling
    Mudri, Dunja
    Bilic Curcic, Ines
    Mestrovic, Lucija
    Mihaljevic, Ivica
    Kizivat, Tomislav
    METABOLITES, 2023, 13 (02)
  • [24] Autophagy and the Wnt signaling pathway: A focus on Wnt/β-catenin signaling
    Lorzadeh, Shahrokh
    Kohan, Leila
    Ghavami, Saeid
    Azarpira, Negar
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2021, 1868 (03):
  • [25] Effects of parathyroid hormone on Wnt signaling pathway in bone
    Kulkarni, NH
    Halladay, DL
    Miles, RR
    Gilbert, LM
    Frolik, CA
    Galvin, RJS
    Martin, TJ
    Gillespie, MT
    Onyia, JE
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 95 (06) : 1178 - 1190
  • [26] Wnt and hedgehog signaling pathways in bone development
    Day, Timothy F.
    Yang, Yingzi
    JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2008, 90A : 19 - 24
  • [27] Editorial: Sclerostin and WNT signaling - The pathway to bone strength
    Ott, SM
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (12): : 6741 - 6743
  • [28] Targeting the Wnt signaling pathway to augment bone formation
    Shahnazari M.
    Yao W.
    Corr M.
    Lane N.E.
    Current Osteoporosis Reports, 2008, 6 (4) : 142 - 148
  • [29] Wnt signaling pathway and its significance for melanoma development
    Kulikova, K. V.
    Kibardin, A. V.
    Gnuchev, N. Y.
    Georgiev, G. P.
    Larin, S. S.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2012, (03) : 107 - 111
  • [30] The Wnt signaling pathway and its role in tumor development
    Lustig, B
    Behrens, J
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (04) : 199 - 221